Benralizumab + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Eosinophilic Gastritis
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Trial Timeline
Jan 18, 2022 → Feb 13, 2024
NCT ID
NCT05251909About Benralizumab + Placebo
Benralizumab + Placebo is a phase 3 stage product being developed by AstraZeneca for Eosinophilic Gastritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05251909. Target conditions include Eosinophilic Gastritis, Eosinophilic Gastroenteritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05692180 | Phase 3 | Recruiting |
| NCT05251909 | Phase 3 | Terminated |
| NCT04612790 | Phase 3 | Terminated |
| NCT04191304 | Phase 3 | Active |
| NCT04185012 | Phase 3 | Completed |
| NCT03953300 | Approved | Active |
| NCT04053634 | Phase 3 | Completed |
| NCT03470311 | Phase 3 | Completed |
| NCT03473977 | Phase 2/3 | Completed |
| NCT03186209 | Phase 3 | Completed |
| NCT02322775 | Phase 3 | Completed |
| NCT01947946 | Phase 3 | Terminated |
| NCT01928771 | Phase 3 | Completed |
| NCT01914757 | Phase 3 | Completed |
Competing Products
20 competing products in Eosinophilic Gastritis